Laurus Labs Ltd (LAURUSLABS)
Healthcare · Pharmaceuticals · NSE · Updated 1 October 2026
₹1,985.6↑ 135.83% (1Y)
🎯 Key Takeaways
- Revenue grew 11.9% QoQ to ₹2,026 in Q1FY27.
- Market Cap
- ₹1.07 L Cr
- P/E Ratio
- 98.0
- P/B Ratio
- 20.24
- ROE
- 20.6%
- ROCE
- 20.8%
- Debt/Equity
- 0.45
- Div Yield
- 0.06%
- Promoter
- 27.5%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,653 | 1,778 | 1,812 | 2,026 |
| Operating Profit | 283 | 360 | 390 | 514 |
| OPM % | 17.1% | 20.2% | 21.5% | 25.4% |
| Net Profit | 194 | 253 | 282 | 362 |
| EPS | ₹3.61 | ₹4.67 | ₹5.17 | ₹6.81 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 108 | 108 | 108 | 108 |
| Reserves | 4,365 | 4,026 | 5,192 | 4,697 |
| Borrowings | 2,764 | 2,789 | 2,397 | 2,212 |
| Total Liabilities | 9,336 | 8,729 | 10,511 | 9,415 |
| Fixed Assets | 3,858 | 3,573 | 4,371 | 3,978 |
| Investments | 233 | 127 | 309 | 261 |
| Total Assets | 9,336 | 8,729 | 10,511 | 9,415 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +1,624 |
| Investing | -1,089 |
| Financing | -525 |
| Net Cash Flow | +10 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 27.6% | 27.5% | 27.5% | 27.5% |
| FII | 26.2% | 26.5% | 25.8% | 28.0% |
| DII | 11.7% | 12.4% | 14.0% | 13.7% |
| Public | 23.3% | 22.6% | 21.2% | 20.5% |
| # Shareholders | 2,83,678 | 2,80,756 | 2,92,281 | 2,91,653 |
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
📋 Recent Filings
- Announcement2026-09-25Laurus Labs announced that its trading window closes on October 1, 2026, ahead of unaudited quarterly results for September 30, 2026, affecting inside…
- 🔴 Announcement2026-09-18Laurus Labs announced its investor presentation highlighting strong FY26 revenue of ₹6,813 crores, a 23% year-on-year increase, and EBITDA of ₹1,826 c…
- 🔴 Announcement2026-09-15Laurus Labs announced its participation in Goldman Sachs Healthcare CDMO Day on September 22-24, 2026, in Singapore, offering one-on-one and group mee…
- 🔴 Announcement2026-09-10Laurus Labs announced it will attend an in-person investor meeting organized by ICICI Securities in Hyderabad on September 17, 2026, as part of its sc…
- 🔴 Announcement2026-08-31Laurus Labs announced it will attend the Antique Pharma Investor Day in Hyderabad on September 7, 2026, as part of an investor conference. The meeting…
- Announcement2026-08-12Laurus Labs announced its participation in the Motilal Oswal Annual Global Investor Conference on August 19, 2026, in Mumbai, offering one-on-one and …
- Announcement2026-08-10Laurus Labs Limited announced that NSE Sustainability Ratings and Analytics independently assigned an ESG Score of 63 out of 100 for FY 2026, based on…
- Announcement2026-07-30Laurus Labs reported Q1 FY27 revenue of INR2,026 crores, up 29% YoY, with EBITDA margin expanding to 31.8% and PAT at INR368 crores. CDMO revenue grew…
- 🔴 Corporate Action2026-07-27Laurus Labs allotted 62,635 equity shares of Rs.2 each to employees exercising stock options across three schemes on July 27, 2026, increasing paid-up…
- 🔴 Corporate Action2026-07-25Laurus Labs announced that the National Company Law Tribunal approved its scheme to demerge Laurus Synthesis Private Limited and amalgamate its remain…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LAURUSLABS files new disclosures
Track LAURUSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LAURUSLABS — FreeFree account · 2 AI queries/day